

Hossein Jadvar

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6919662/hossein-jadvar-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

130
papers

3,796
citations

33
h-index

58
g-index

145
ext. papers

4,596
ext. citations

5.5
avg, IF

6.24
L-index

#	Paper	IF	Citations
130	Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. <i>Journal of Nuclear Medicine</i> , 2011 , 52, 81-9	8.9	238
129	F-fluciclovine PET-CT and Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1286-1294	21.7	209
128	18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. <i>Journal of Nuclear Medicine</i> , 2009 , 50, 1820-7	8.9	169
127	The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. <i>Journal of Nuclear Medicine</i> , 2012 , 53, 1633-51	8.9	163
126	Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. <i>Radiology</i> , 2002 , 224, 783-7	20.5	151
125	A systematic review on diagnostic accuracy of CT-based detection of significant coronary artery disease. <i>European Journal of Radiology</i> , 2008 , 65, 449-61	4.7	134
124	Competitive advantage of PET/MRI. <i>European Journal of Radiology</i> , 2014 , 83, 84-94	4.7	113
123	Future cancer research priorities in the USA: a Lancet Oncology Commission. <i>Lancet Oncology, The</i> , 2017 , 18, e653-e706	21.7	106
122	Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. <i>Clinical Nuclear Medicine</i> , 2012 , 37, 637-43	1.7	104
121	PSMA Theranostics: Current Status and Future Directions. <i>Molecular Imaging</i> , 2018 , 17, 1536012118776068	5.7	101
120	Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 40 Suppl 1, S5-10	8.8	101
119	PET and PET/CT in pediatric oncology. <i>Seminars in Nuclear Medicine</i> , 2007 , 37, 316-31	5.4	96
118	Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 1195-201	8.9	92
117	Molecular imaging of prostate cancer: PET radiotracers. <i>American Journal of Roentgenology</i> , 2012 , 199, 278-91	5.4	81
116	Is There Use for FDG-PET in Prostate Cancer?. <i>Seminars in Nuclear Medicine</i> , 2016 , 46, 502-506	5.4	81
115	Diagnostic utility of FDG PET in multiple myeloma. <i>Skeletal Radiology</i> , 2002 , 31, 690-4	2.7	76
114	Sodium 18F-fluoride PET/CT of bone, joint, and other disorders. <i>Seminars in Nuclear Medicine</i> , 2015 , 45, 58-65	5.4	69

113	Molecular imaging of prostate cancer with PET. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 1685-8	8.9	65
112	Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET. <i>Nature Reviews Urology</i> , 2009 , 6, 317-23	5.5	60
111	Appropriate Use Criteria for F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 2026-2037	8.9	57
110	[F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma. <i>Journal of Computer Assisted Tomography</i> , 2007 , 31, 223-8	2.2	57
109	[F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2008 , 13, 42-7	4.2	55
108	Radiotheranostics in Cancer Diagnosis and Management. <i>Radiology</i> , 2018 , 286, 388-400	20.5	52
107	Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1963-1996	2.2	51
106	Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 4, 580-601	2.2	51
105	Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment. <i>American Journal of Roentgenology</i> , 2017 , 209, 277-288	5.4	46
104	Evaluation of Rare Tumors with [F-18]Fluorodeoxyglucose Positron Emission Tomography. <i>Molecular Imaging and Biology</i> , 1999 , 2, 153-158		45
103	Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors. <i>Molecular Imaging and Biology</i> , 2018 , 20, 501-509	3.8	43
102	PSMA PET in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015 , 56, 1131-2	8.9	40
101	The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma. <i>Clinical Nuclear Medicine</i> , 2000 , 25, 48-51	1.7	40
100	Targeted β particle therapy of bone metastases in prostate cancer. <i>Clinical Nuclear Medicine</i> , 2013 , 38, 966-71	1.7	38
99	FDG PET in Prostate Cancer. <i>PET Clinics</i> , 2009 , 4, 155-61	2.2	37
98	FDG PET in suspected recurrent and metastatic prostate cancer. <i>Oncology Reports</i> , 2003 , 10, 1485-8	3.5	37
97	[F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland. <i>Annals of Nuclear Medicine</i> , 2008 , 22, 787-93	2.5	31
96	18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA \geq 1 ng/mL After Definitive Primary Treatment. <i>Clinical Nuclear Medicine</i> , 2019 , 44, e128-e132	1.7	30

95	One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015 , 30, 195-9	3.9	29
94	Targeted Radionuclide Therapy: Practical Applications and Future Prospects. <i>Biomarkers in Cancer</i> , 2016 , 8, 35-8	7	29
93	Musculoskeletal system. <i>Seminars in Nuclear Medicine</i> , 2004 , 34, 254-61	5.4	29
92	Applications of PET/CT and PET/MR Imaging in Primary Bone Malignancies. <i>PET Clinics</i> , 2018 , 13, 623-634	4.2	27
91	Update on advances in molecular PET in urological oncology. <i>Japanese Journal of Radiology</i> , 2016 , 34, 470-85	2.9	25
90	PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 25S-29S	8.9	25
89	Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 19S-24S	8.9	25
88	PET in pediatric diseases. <i>Radiologic Clinics of North America</i> , 2005 , 43, 135-52	2.3	23
87	A reusable perfusion supporting tissue-mimicking material for ultrasound hyperthermia phantoms. <i>Medical Physics</i> , 1990 , 17, 380-90	4.4	23
86	Positron Emission Tomography in Prostate Cancer: Summary of Systematic Reviews and Meta-Analysis. <i>Tomography</i> , 2015 , 1, 18-22	3.1	23
85	Preservation of retinotopic map in retinal degeneration. <i>Experimental Eye Research</i> , 2012 , 98, 88-96	3.7	22
84	Evolving cardiac conduction phenotypes in developing zebrafish larvae: implications to drug sensitivity. <i>Zebrafish</i> , 2010 , 7, 325-31	2	22
83	Pharmacologic interventions in nuclear radiology: indications, imaging protocols, and clinical results. <i>Radiographics</i> , 2002 , 22, 477-90	5.4	22
82	Glucose metabolism of human prostate cancer mouse xenografts. <i>Molecular Imaging</i> , 2005 , 4, 91-7	3.7	22
81	Clinical Nononcologic Applications of PET/CT and PET/MRI in Musculoskeletal, Orthopedic, and Rheumatologic Imaging. <i>American Journal of Roentgenology</i> , 2018 , 210, W245-W263	5.4	21
80	2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography/computed tomography imaging evaluation of esophageal cancer. <i>Molecular Imaging and Biology</i> , 2006 , 8, 193-200	3.8	20
79	Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: potential role of other positron emission tomography radiotracers. <i>Seminars in Nuclear Medicine</i> , 2012 , 42, 247-54	5.4	19
78	Effect of atropine and sincalide on the intestinal uptake of F-18 fluorodeoxyglucose. <i>Clinical Nuclear Medicine</i> , 1999 , 24, 965-7	1.7	19

77	Actinomycosis mimicking anastomotic recurrent esophageal cancer on PET-CT. <i>Clinical Nuclear Medicine</i> , 2006 , 31, 646-7	1.7	18
76	SPECT and PET in the evaluation of coronary artery disease. <i>Radiographics</i> , 1999 , 19, 915-26	5.4	18
75	FDG PET-CT demonstration of Sjogren's sialoadenitis. <i>Clinical Nuclear Medicine</i> , 2005 , 30, 698-9	1.7	16
74	Molecular Imaging of Prostate Cancer: A Concise Synopsis. <i>Molecular Imaging</i> , 2009 , 8, 7290.2009.000103.7	3.7	15
73	The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo. <i>Prostate</i> , 2010 , 70, 1359-70	4.2	15
72	PET in the Diagnostic Management of Soft Tissue Sarcomas of Musculoskeletal Origin. <i>PET Clinics</i> , 2018 , 13, 609-621	2.2	15
71	Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases. <i>Clinical Nuclear Medicine</i> , 2018 , 43, e226-e231	1.7	15
70	Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2019 , 60, 1524-1530	8.9	14
69	Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastases. <i>Radiology</i> , 2015 , 274, 624-5	20.5	14
68	Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma. <i>Hellenic Journal of Nuclear Medicine</i> , 2009 , 12, 26-9	0.6	14
67	Role of Imaging in Prostate Cancer. <i>PET Clinics</i> , 2009 , 4, 135-8	2.2	12
66	Oligometastatic Prostate Cancer: Molecular Imaging and Clinical Management Implications in the Era of Precision Oncology. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1338-1339	8.9	10
65	FDG PET/CT demonstration of pancreatic metastasis from prostate cancer. <i>Clinical Nuclear Medicine</i> , 2011 , 36, 961-2	1.7	10
64	Science to Practice: Does FDG Differentiate Morphologically Unstable from Stable Atherosclerotic Plaque?. <i>Radiology</i> , 2017 , 283, 1-3	20.5	9
63	Targeted Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020 , 35, 475-484	3.9	9
62	F-NaF/RaCl theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome. <i>British Journal of Radiology</i> , 2018 , 91, 20170948	3.4	9
61	Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer. <i>Abdominal Radiology</i> , 2016 , 41, 889-98	3	9
60	Targeted Prostate Gland Biopsy With Combined Transrectal Ultrasound, mpMRI, and 18F-FMAU PET/CT. <i>Clinical Nuclear Medicine</i> , 2015 , 40, e426-8	1.7	9

59	[18F]-2? -Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in Prostate Cancer: Initial Preclinical Observations. <i>Molecular Imaging</i> , 2012 , 11, 7290.2012.00004	3.7	9
58	[18F]-2PFluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in prostate cancer: initial preclinical observations. <i>Molecular Imaging</i> , 2012 , 11, 426-32	3.7	9
57	Management of Primary Osseous Spinal Tumors with PET. <i>PET Clinics</i> , 2019 , 14, 91-101	2.2	9
56	Can Choline PET Tackle the Challenge of Imaging Prostate Cancer?. <i>Theranostics</i> , 2012 , 2, 331-2	12.1	8
55	Choline autoradiography of human prostate cancer xenograft: effect of castration. <i>Molecular Imaging</i> , 2008 , 7, 147-52	3.7	8
54	Molecular imaging of prostate cancer: a concise synopsis. <i>Molecular Imaging</i> , 2009 , 8, 56-64	3.7	8
53	PSMA PET: Transformational Change in Prostate Cancer Management?. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 228-229	8.9	8
52	American College of Radiology and Society of Nuclear Medicine and Molecular Imaging Joint Credentialing Statement for PET/MR Imaging: Brain. <i>Journal of Nuclear Medicine</i> , 2015 , 56, 642-5	8.9	7
51	The reproductive tract. <i>Seminars in Nuclear Medicine</i> , 2004 , 34, 262-73	5.4	7
50	Prostate cancer. <i>Methods in Molecular Biology</i> , 2011 , 727, 265-90	1.4	7
49	PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 1803-1811	4.9	7
48	Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. <i>Journal of Nuclear Medicine</i> , 2021 ,	8.9	7
47	Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria. <i>Theranostics</i> , 2020 , 10, 3254-3262	12.1	6
46	Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 552-562	8.9	6
45	The SNMMI and EANM practice guideline for tele-nuclear medicine 2.0. <i>Journal of Nuclear Medicine Technology</i> , 2014 , 42, 15-9	1.1	6
44	Imaging Cellular Proliferation in Prostate Cancer with Positron Emission Tomography. <i>Asia Oceania Journal of Nuclear Medicine and Biology</i> , 2015 , 3, 72-6	0.7	6
43	Prognostic Utility of PET in Prostate Cancer. <i>PET Clinics</i> , 2015 , 10, 255-63	2.2	5
42	Colonic FDG uptake pattern in subjects receiving oral contrast with no known or suspected colonic disease. <i>Clinical Nuclear Medicine</i> , 2011 , 36, 754-6	1.7	5

41	ACR-ASTRO practice guideline for the performance of therapy with unsealed radiopharmaceutical sources. <i>Clinical Nuclear Medicine</i> , 2011 , 36, e72-80	1.7	5
40	Fusion positron emission tomography-computed tomography demonstration of epidural metastases. <i>Clinical Nuclear Medicine</i> , 2004 , 29, 39-40	1.7	5
39	Procedure guideline for telenuclear medicine 1.0. <i>Journal of Nuclear Medicine</i> , 2002 , 43, 1410-3	8.9	5
38	Treatment Response Assessment of Skeletal Metastases in Prostate Cancer with F-NaF PET/CT. <i>Nuclear Medicine and Molecular Imaging</i> , 2019 , 53, 247-252	1.9	4
37	Adenocarcinoma in an Indiana pouch on PET-CT. <i>Clinical Nuclear Medicine</i> , 2007 , 32, 57-8	1.7	4
36	Utility of a stimulus artifact suppressor for transesophageal pacing. <i>American Journal of Cardiology</i> , 1990 , 65, 393-4	3	4
35	Low-count whole-body PET with deep learning in a multicenter and externally validated study. <i>Npj Digital Medicine</i> , 2021 , 4, 127	15.7	4
34	ACR and SNMMI Joint Credentialing Statement for PET/MRI of the Body. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1174-1176	8.9	3
33	SNMMI Comment on the 2016 Society of Surgical Oncology "Choosing Wisely" Recommendation on the Use of PET/CT in Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 11-12	8.9	3
32	Preclinical evaluation of a Cu-labeled disintegrin for PET imaging of prostate cancer. <i>Amino Acids</i> , 2019 , 51, 1569-1575	3.5	3
31	Highlights of articles published in annals of nuclear medicine 2016. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 1928-1933	8.8	3
30	Prostate-Specific Antigen and Prostate-Specific Antigen Kinetics in Predicting F-Sodium Fluoride Positron Emission Tomography-Computed Tomography Positivity for First Bone Metastases in Patients with Biochemical Recurrence after Radical Prostatectomy. <i>World Journal of Nuclear Medicine</i> , 2017 , 14, 222-227	0.6	3
29	Salvage Therapies After 18F-Fluciclovine Detected Prostate Cancer Recurrences. <i>Clinical Nuclear Medicine</i> , 2020 , 45, 668-671	1.7	3
28	Radiotheranostics in Prostate Cancer: Introduction and Overview. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1S-2S	8.9	3
27	Duplex Doppler sonography: is there clinical relevance to elevated renal vein velocity in kidney transplants?. <i>Clinical Imaging</i> , 2016 , 40, 1237-1245	2.7	3
26	Role of F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: Expert Panel Narrative Review. <i>American Journal of Roentgenology</i> , 2021 , 216, 851-859	5.4	3
25	SNMMI Leadership Update: Developing Evidence-Based Appropriate Use Criteria under the Protecting Access to Medicare Act of 2014. <i>Journal of Nuclear Medicine</i> , 2015 , 56, 20N	8.9	3
24	Gallium-68-Labeled Prostate-Specific Membrane Antigen-11 PET/CT of Prostate and Nonprostate Cancers. <i>American Journal of Roentgenology</i> , 2019 , 213, 286-299	5.4	2

23	Multimodal Imaging in Focal Therapy Planning and Assessment in Primary Prostate Cancer. <i>Clinical and Translational Imaging</i> , 2017 , 5, 199-208	2	2
22	The Use of Imaging in the Prediction and Assessment of Cancer Treatment Toxicity. <i>Diagnostics</i> , 2017 , 7,	3.8	2
21	A review of prostate cancer imaging, positron emission tomography, and radiopharmaceutical-based therapy. <i>Canadian Urological Association Journal</i> , 2020 , 14, 130-138	1.2	2
20	Incidental Detection of Meningioma by 18F-FMAU PET/CT in a Patient With Suspected Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2018 , 43, e245-e246	1.7	2
19	Point: The Existential Threat to Nuclear Medicine. <i>Journal of the American College of Radiology</i> , 2018 , 15, 384-386	3.5	2
18	Management Impact of Ga-DOTATATE PET/CT in Neuroendocrine Tumors. <i>Nuclear Medicine and Molecular Imaging</i> , 2021 , 55, 31-37	1.9	2
17	Advances in Imaging of Nonthyroid Endocrine Neoplasms. <i>Problems in General Surgery</i> , 2003 , 20, 11-20		1
16	Invited Commentary: Nuclear Theranostics-The Path Forward. <i>Radiographics</i> , 2020 , 40, 1741-1742	5.4	1
15	Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre.. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022 , 1	8.8	1
14	Targeted Therapy in non-prostate malignancies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 1	8.8	0
13	Reply: Staging, Restaging, and Treatment Response Assessment in Lymphomas: What We Should Know. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 715-716	8.9	
12	Influence of trigger PSA and PSA kinetics on (11)C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 498-9; author reply 499-500	8.9	
11	Yosemite, California. <i>American Journal of Roentgenology</i> , 2003 , 181, 302-302	5.4	
10	Cancun, Mexico. <i>American Journal of Roentgenology</i> , 2003 , 181, 1092-1092	5.4	
9	Room with a View (North Coast of Aruba). <i>American Journal of Roentgenology</i> , 2001 , 177, 806-806	5.4	
8	Raw and Ripe. <i>American Journal of Roentgenology</i> , 2001 , 177, 886-886	5.4	
7	Death Valley, California. <i>American Journal of Roentgenology</i> , 2002 , 179, 1244-1244	5.4	
6	Gone Fishing. <i>American Journal of Roentgenology</i> , 2000 , 175, 140-140	5.4	

5 Targeted Radionuclide Therapy and Immunotherapy of Metastatic Prostate Cancer **2022**, 449-456

4 Editorial Comment. *Journal of Urology*, **2019**, 202, 420-421

2.5

3 Prostate Cancer Lymphangitic Pulmonary Carcinomatosis: Appearance on 18F-FDG PET/CT and 18F-DCFPyL PET/CT. *Clinical Nuclear Medicine*, **2020**, 45, 727-729

1.7

2 Imaging of Glycolysis with 18F-FDG PET **2017**, 87-94

1 Effect of Androgen on Normal Biodistribution of [F]-2PFluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in Athymic Non-tumor-bearing Male Mice. *Anticancer Research*, **2017**, 37, 475-479

2.3